Search Results
105 Results Found for “comparative study”
Both intracerebral hemorrhage and ischemic stroke continue to be the leading causes of disability and the second leading causes of death worldwide.1,2 The burden is largest in low- and middle-income countries, which have seen rapid recent population growth. Large vessel ...
In this narrative review, we aim to introduce the reader to the history of calcitonin gene-related peptide (CGRP) discovery and its involvement in migraine pathophysiology. We will then look at drug development and clinical trials in migraine. We will additionally ...
Between 60% and 80% of cases with dementia worldwide are caused by Alzheimer’s disease (AD), making it the most prevalent type of dementia.1 As of 2025, approximately 60 million people worldwide are affected by dementia, and by 2050, projections suggest a rise to nearly 210 ...
In general, headaches can be classified into primary headaches (where no underlying disease is found) and secondary headaches (where a predefined condition is the cause of the headache). According to the International Classification of Headache Disorders, third edition (ICHD-3), primary ...
The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Congress, held in Barcelona, brought together over 9,600 global experts under the theme “A New Era of Precision.” This report, developed in collaboration with the National Multiple Sclerosis Society, highlights key breakthroughs in diagnosis, treatment, and lifestyle interventions—including advances in ocrelizumab, BTK inhibitors, myelin repair strategies, and early biomarkers. With new insights into cognition, menopause, and precision medicine, ECTRIMS 2025 underscored the shift toward truly personalised, data-driven MS care.
Data presented at World Sleep 2025 from two global narcolepsy phase III trials, FirstLight (TAK‑861‑3001) (NCT06470828) and RadiantLight (TAK‑861‑3002)1,2, evaluating oveporexton (TAK‑861), an investigational oral orexin receptor 2 (OX2R)‑selective agonist for narcolepsy type 1 (NT1)
Seizures are one of the most frequent neurological disorders in neonates − the incidence of seizures in infants born at term is 1–3 per 1,000 live births, and is even higher in both preterm and very-low-birth-weight infants at 1–13 per 1,000 live births.1 Seizures may ...
The phase 3b SMART study has shown that 83% of paediatric patients with spinal muscular atrophy (SMA) weighing between 8.5 and 21 kg achieved significant motor improvements following treatment with intravenous onasemnogene abeparvovec in a recent article published in Neurology.
Huntington’s disease (HD) is a neurodegenerative disease inherited in an autosomal dominant manner. It is caused by an expansion of cytosine, adenine, guanine (CAG) repeats within the huntingtin (HTT) gene, which is located on chromosome 4. This pathological expansion of ...
Neuromyelitis optica spectrum disorder (NMOSD) is a rare inflammatory autoimmune disease of the central nervous system (CNS) with a worldwide distribution.1 The first clinical description of NMOSD was made a century ago by Devic and Gault, who documented patients with ...
Acute disseminated encephalomyelitis (ADEM), first characterized in 1931,1 is a non-specific clinical syndrome of polyfocal central nervous system (CNS) inflammatory demyelination; it is characterized by encephalopathy and large, poorly demarcated cerebral white matter lesions.2,3 Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), ...
Hirayama disease (HD) is a lower motor neurologic disorder that manifests in young males in their early 20s, manifesting with gradually progressive weakness and wasting of C7-T1 innervated muscles. Dynamic magnetic resonance imaging (MRI) clinches the diagnosis, and treatment ...
Expert interview with Prof. Tomas Kalincik, Dame Kate Campbell Professorial Fellow, Head of the Clinical Outcomes Research (CORe) Unit, University of Melbourne and MS Centre, Royal Melbourne Hospital, Victoria, Melbourne, Australia. Together with his research group, CORe, Prof Tomas Kalincik ...
While Alzheimer’s disease (AD), the most common cause of dementia, is perhaps best characterized by cognitive decline, more than 90% of patients with dementia exhibit behavioural and psychological symptoms of dementia.1 The Cache County Study on Memory in Aging describes ...
Corticosteroids can improve muscle function in boys with Duchenne muscular dystrophy and are commonly prescribed for newly diagnosed patients. Dr Michela Guglieri (Newcastle University, Newcastle upon Tyne, United Kingdom) discusses a randomized, double-blind, parallel-group clinical trial investigating comparative safety and ...
Neuropathic pain arises from injury to or disease in the somatosensory nervous system.1 Normal sensation and pain sensation are both impaired and patients may present with peculiar painful characteristics such as allodynia and hyperalgesia.2 Central neuropathic pain includes pain from ...
Migraine prevention medication is recommended for: (1) frequent headaches (generally defined as at least four migraines per month that are associated with some degree of impairment); (2) migraines that significantly interfere with a patient’s daily activities despite acute treatment; (3) migraine with ...
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disorder of the central nervous system that is characterised by episodes of neurological dysfunction and eventually, neurodegeneration and the progressive accumulation of disability.1,2 Approximately 85% of patients with MS initially present with relapsing-remitting ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
